Business Context and Reporting Period
This Form 8-K Current Report was filed by Daré Bioscience, Inc. on March 31, 2023. The filing discloses the entry into a material definitive agreement to establish an "at-the-market" equity offering program.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sales agreement.
Material Changes and Agreements
On March 31, 2023, the Company entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. to act as sales agents. Key terms include:
- Program Type: "At-the-market" equity offering allowing the sale of common stock from time to time.
- Commission: The Company agreed to pay the Sales Agents a commission of 3.0% of the gross proceeds from sales.
- Control: The Company retains the right to set parameters for sales, including maximum share amounts, time periods, daily limits, and minimum prices.
- Flexibility: The Company has no obligation to sell shares and may suspend the program at its sole discretion. The agreement may be terminated by either party with five days' prior notice.
- Registration: Shares will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-254862).
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary regarding future earnings. The document notes that the Sales Agreement includes customary representations, warranties, and indemnification obligations. It explicitly states that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and trading volume on the Nasdaq Capital Market to assess the potential impact of future "at-the-market" sales.
- Review the Company's most recent 10-K or 10-Q filings for actual cash position and liquidity needs, as this 8-K does not disclose financial status.
- Monitor future filings for the actual volume of shares sold under this program and the resulting dilution to existing shareholders.
- Confirm the status of the underlying Form S-3 shelf registration statement (File No. 333-254862).